Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?

Combination chemotherapy used to treat patients with aggressive non-Hodgkin's lymphoma is associated with neutropenia and subsequent infection, hospital admission and treatment delays. Haematopoietic growth factors (HGF) can prevent neutropenia and improve quality of life. We undertook a meta-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hackshaw, A, Sweetenham, J, Knight, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409679/
https://www.ncbi.nlm.nih.gov/pubmed/15054445
http://dx.doi.org/10.1038/sj.bjc.6601708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409679/
https://www.ncbi.nlm.nih.gov/pubmed/15054445
http://dx.doi.org/10.1038/sj.bjc.6601708

Ejemplares similares